Table A1.
Clinicopathologic Characteristics of YTMA 49 and YTMA 130 Cohorts
| Characteristic | YTMA 49 Cohort |
YTMA 130 Cohort |
||
|---|---|---|---|---|
| No. | % | No. | % | |
| All patients | 619 | 389 | ||
| Age, years | ||||
| < 50 | 164 | 26.5 | 129 | 33.2 |
| ≥ 50 | 443 | 71.6 | 249 | 64.0 |
| Unknown | 12 | 1.9 | 11 | 2.8 |
| Nodal status | ||||
| Positive | 317 | 51.2 | 68 | 17.5 |
| Negative | 292 | 47.2 | 229 | 58.9 |
| Unsampled/unknown | 10 | 1.6 | 92 | 23.7 |
| Tumor size, mm | ||||
| ≤ 2 | 272 | 43.9 | 269 | 69.2 |
| 2-5 | 196 | 31.7 | 77 | 19.8 |
| ≥ 5 | 95 | 15.3 | 4 | 1.0 |
| Unknown | 56 | 9.0 | 39 | 10.0 |
| ER (IHC) | ||||
| Positive (1–3) | 331 | 53.5 | 220 | 56.6 |
| Negative (0) | 288 | 46.5 | 169 | 43.4 |
| Unknown | 0 | 0 | 0 | 0 |
| PgR (IHC) | ||||
| Positive (1–3) | 302 | 48.8 | 37 | 9.5 |
| Negative (0) | 295 | 47.7 | 343 | 88.2 |
| Unknown | 22 | 3.6 | 9 | 2.3 |
| HER2 (IHC) | ||||
| Positive (2–3) | 109 | 17.6 | 39 | 10.0 |
| Negative (0–1) | 495 | 80.0 | 337 | 86.6 |
| Unknown | 15 | 2.4 | 13 | 3.3 |
| Follow-up, months | ||||
| Median | 104.1 | 97.0 | ||
| Range | 2.4–646.5 | 2–327 | ||
Abbreviations: YTMA, Yale tissue microarray [cohort]; ER, estrogen receptor; IHC, immunohistochemistry; PgR, progesterone receptor; HER2, human epithelial growth factor receptor 2.